LAVA Therapeutics Announces Appointment of New Directors to the Board
January 06 2023 - 1:07PM
LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage
immuno-oncology company focused on developing its proprietary
Gammabody™ platform of bispecific gamma delta T cell engagers,
today announced the appointment of two new directors to its Board
of Directors. Peter A. Kiener, DPhil, a research and development
veteran in biologics, immunotherapy, and biopharmaceuticals, and
Mary Wadlinger, a recognized leader in high-growth biotechnology
and biopharmaceuticals organizational and business issues were
appointed effective January 1, 2023. Additionally, Guido Magni,
M.D., Ph.D. will step down from his role on the LAVA Board.
“Dr. Kiener and Ms. Wadlinger bring a wealth of knowledge in
their respective fields along with deep expertise in biotechnology.
Dr. Kiener’s extensive experience in drug development from
discovery through approval combined with Mary’s expertise in
biotechnology organizational dynamics will help advance LAVA’s
strategy and achieve key milestones for our pipeline of bispecific
gamma delta T cell engagers,” said Stephen Hurly, president and
chief executive officer of LAVA Therapeutics.
“Since joining our board in 2018, Dr. Magni has made invaluable
contributions to LAVA, including lead program selection, launching
our first clinical trials and seeing LAVA through a successful
initial public offering. On behalf of the entire Board, I would
like to thank him for his impactful contributions, expert guidance,
and dedicated service to our company,” added Hurly.
“It has been both an honor and a privilege to have served on
LAVA’s Board for the past four years and I am extremely proud of
our accomplishments and the progress we have made to develop new
and promising therapeutics for people with cancer,” said Guido
Magni, M.D., Ph.D. “I am especially excited about LAVA’s future and
further development of the Gammabody™ platform, which has the
potential to transform the cancer treatment landscape.”
Dr. Peter Kiener is an industry veteran with extensive
experience in both biologics and immunotherapy, and
biopharmaceutical research and development. Previously, he was
chief scientific officer at Sucampo, which was acquired by
Mallinckrodt and served as chief scientific officer of Ambrx Inc.,
a clinical-stage biopharmaceutical company focused on the
development of antibody-drug conjugates (ADCs). Dr. Kiener was also
president and co-founder of Zyngenia Inc., an early-stage
biopharmaceutical company and served as executive vice president
and global head of biologics research and development at MedImmune
LLC, the global biologics arm of AstraZeneca. He received a
Bachelor of Science from Lancaster University in Lancaster, UK and
his DPhil from Oxford University, Sir William Dunn School of
Pathology.
Ms. Wadlinger brings 25 years of experience as a strategic human
resources leader in biotechnology and global biopharmaceuticals.
Most recently, Ms. Wadlinger was senior vice president and Chief
Human Resources Officer at Forma Therapeutics where she led the
organization and people strategy through critical growth and
reorganization as the company transformed from drug discovery to a
fully integrated drug development and commercial readiness company.
Prior to Forma, she served as vice president, human resources at
Millennium Pharmaceuticals, a subsidiary of Takeda Pharmaceuticals
where she served as a key leader in numerous corporate
transformations, growth initiatives, M&A activity, and overall
integration within Takeda. Ms. Wadlinger earned a Bachelor of
Science degree in Finance from the University of Maine Business
School.
About LAVA TherapeuticsLAVA Therapeutics N.V.
is a clinical-stage immuno-oncology company utilizing its
proprietary Gammabody™ platform to develop a portfolio of
bispecific gamma delta T cell engagers for the potential treatment
of solid and hematologic malignancies. The Company utilizes
bispecific antibodies engineered to selectively kill cancer cells
by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector
functions upon cross-linking to tumor-associated antigens.
LAVA-051, the Company’s lead candidate for the treatment of
multiple myeloma, chronic lymphocytic leukemia, and acute myeloid
leukemia, is enrolling patients in a Phase 1/2a clinical study
(NCT04887259). A Phase 1/2a clinical study to evaluate LAVA-1207 in
patients with metastatic castration-resistant prostate cancer
(mCRPC) is also enrolling (NCT05369000). For more information,
please visit www.lavatherapeutics.com, and follow us
on LinkedIn, Twitter and YouTube.
CONTACTSInvestor
Relationsir@lavatherapeutics.com
Argot Partners (IR/Media)212-600-1902lava@argotpartners.com
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Sep 2024 to Oct 2024
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Oct 2023 to Oct 2024